Introduction
Inactivation of the retinoblastoma-susceptibility gene (Rb1) is linked to tumorigenesis in humans (Weinberg, 1991) . The Rb1-encoded protein (pRB) forms speci®c complexes with members of the E2F family of cellular transcription factors. The promoter regions of certain important growth control genes such as c-myc, B-myb, cdc2, DNA polymerase a, DHFR, TK, cyclin D and cyclin E have been found to contain the sequences to which pRB-E2F complexes bind (Nevins, 1992; Blake and Azizkhan, 1989; Dalton, 1992; Hamel et al., 1992; Lam and Watson, 1993; Means et al., 1992; Thalmeier et al., 1989; Motokura and Arnold, 1993; DeGregori et al., 1995; Duronio and O'Farrell, 1995) . It appears that pRB-E2F complexes can suppress the expression of these genes which are critical to cell proliferation while E2F can activate their expression. Therefore, depending on whether pRB-E2F complexes or E2F are bound, the genes which regulate cell cycle progression can be either in the mode of repression or activation, respectively (reviewed by Whyte, 1995; Muller, 1995) .
E2F has been known to be a family of proteins including E2F1, E2F2, E2F3, E2F4, and E2F5 (reviewed by La Thangue, 1994; Weinberg, 1995; Slansky and Farnham, 1995) . pRB mainly associates with E2F1, E2F2 and E2F3 (Helin et al., 1992; Kaelin et al., 1992; Shan et al., 1992; Ivey-Hoyle et al., 1993; . The pRB-related proteins, p107 and p130, associate with E2F4 and E2F5 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995; Sardet et al., 1995; Vairo et al., 1995) . Introduction of the DNA binding fragments of one E2F species, E2F1 Helin et al., 1992; Shan et al., 1992) , was shown to block pRB-imposed large cell formation by alleviating the transcriptional repression by pRB-E2F complexes and to inhibit adenovirus E1A-induced E2F-dependent S phase entry (Qin et al., 1995; Dobrowolski et al., 1994) . Expression of E2F1 molecules capable of DNA binding and transactivation drove cells from either quiescence or the pRBinduced G 1 /G 0 block into S phase Qin et al., 1994 Qin et al., , 1995 Zhu et al., 1993; Shan and Lee, 1994; Kowalik et al., 1995) . E2F1 only binds to the underphosphorylated pRB and the timing of cell cycle arrest induced by pRB coincides with the presence of its underphosphorylated form Buchkovich et al., 1989; Chen et al., 1989; DeCaprio et al., 1989; Mihara et al., 1989; Hinds et al., 1992; Qin et al., 1992; Dulic et al., 1992; Ko et al., 1992) . The loss of pRB function either by mutation or association with viral oncoproteins is linked with uncontrolled cell proliferation and is accompanied by the release of transcription factors such as E2F1 (reviewed by Nevins, 1992; La Thangue, 1994; Weinberg, 1995) . These studies reinforced the eector-target relationship of pRB and E2F1. Therefore, it is possible that pRB exerts its normal G 1 checkpoint function, at least in part, by negatively regulating E2F1. However, the role of E2F1 in the alteration of the checkpoint controls in Rb 7/7 tumors remains to be elucidated.
A number of laboratories have demonstrated that overexpression of E2F1 can lead to oncogenesis (Johnson et al., 1994a; Singh et al., 1994; Jooss et al., 1995; Xu et al., 1995) . Interestingly, the promoter region of the E2F1 gene also contains speci®c E2F-binding DNA sites, indicating that E2F1 may regulate its own expression (Johnson et al., 1994b; Neuman et al., 1994) . pRB, through binding to E2F, switches E2F sites from positive to negative elements, suggesting that pRB-E2F complexes actively repress gene transcription (Weintraub et al., 1992 (Weintraub et al., , 1995 . These data, along with previous studies, suggest that pRB-E2F transcriptional complexes normally function as an eector in controlling the transition of E2F1 from a protooncogene to an active oncogene by tightly regulating E2F1 expression. Recently, homozygous null mutation of E2F1 in mice was found to be linked with hyperproliferation and tumor development at an older stage of development (Yamasaki et al., 1996; Field et al., 1996) . E2F1 becomes the ®rst cellular protein demonstrated to act as an oncogene as well as a tumor suppressor. Moreover, the tumor development of E2F1 knockout mice may result from the failure of pRB to transduce its tumor suppression signal since E2F1 is a downstream target of pRB. In this report, we investigated the biological eects of E2F1 as an eector, not as a target of pRB. We speculate that during the transformation process, loss of functional pRB triggers an uncontrolled E2F1 feedback loop which might contribute to tumorigenesis. Through the use of E2F1 dominant negative mutants, we demonstrated that E2F1 may have two dierent functions before and after the cell cycle restriction point. These ®ndings give insights into the role of E2F1 in the tumorigenesis process in which cells lose functional pRB.
Results

G 1 cell increase induced by dominant interfering mutants of E2F1
We began experiments with the human primary Rb 7/7 osteosarcoma cells SAOS2 and two types of E2F1 mutants ( Figure 1a ). One mutant (E2F1a) is an Nterminal fragment containing the DNA binding domain but lacking the C-terminal transactivation segment and the zipper sequences. This mutant was designed to speci®cally interfere with E2F1 transactivation by competing for DNA binding. Previously, it was demonstrated that this mutant was capable of binding to DNA and its expression was sucient to block the pRB-induced phenotype (Qin et al., 1995) . The other mutant (E2F1b) is defective in both DNA binding and pRB binding (Qin et al., 1995) . We reasoned that if E2F1, as an eector, targets a cellular protein(s), this mutant may function as a dominant negative inhibitor at the level of protein-protein interaction. In the ®rst set of experiments, both mutants were individually transfected into SAOS2 cells along with the pre-B cell surface marker CD19. Three days after transfection, cells were coated with an anti-CD19 monoclonal antibody and an FITCconjugated secondary antibody to detect transfected cells. Cell cycle distribution of CD19-positive cells was examined by FACS analysis using propidium iodide staining. Cells transfected with both E2F1 mutants exhibited a signi®cant increase in the G 1 cell population, comparable to the cells transfected with pRB (Figure 1b and c) . To rule out the possibility that the G 1 cell increase induced by E2F1b is a nonspeci®c eect due to the expression of a transactivation domain, we examined the cell cycle distribution of cells transfected with the plasmid encoding the activation domain of herpes simplex virus VP16 fused to the tet repressor (Gossen and Bujard, 1992) . As shown in Figure 1c , no cell cycle eect was observed, suggesting that introduction of a transactivation domain alone is not enough for the E2F1b eect. Next we tested the eect of E2F1 mutants on human Rb 7/7 cervical carcinoma cells C33A. G 1 cell increase was also observed by transfection of E2F1 mutants in these cells, although to a lesser extent than in SAOS2 cells (data not shown).
Two dierent mechanisms underlying the G 1 cell increase induced by E2F1a and E2F1b
The G 1 population increase could be explained by two dierent models: slow progression of G 1 phase or blockage in G 1 . In the ®rst case, long-term culture of the cells should give rise to macroscopic colonies while cells in the latter case should not. Plasmids encoding these E2F1 mutants along with a plasmid encoding a G418-resistance gene were introduced into SAOS2 cells and a long-term colony growth assay was performed. The culture transfected with E2F1a gave rise to signi®cantly fewer colonies than the culture transfected with the control plasmid. E2F1b only showed a slight decrease in the colony number compared with the control plasmid, even though E2F1b induced a greater G 1 cell increase eect based on FACS analysis (Table 1 and Figure 1b) . Generation of stable cell lines expressing E2F1a was dicult. Subcloning of 20 colonies gave rise to only two E2F1a expressing cell lines. Both of these two cell lines expressed E2F1a at a level lower than endogenous E2F1. In contrast, immuno¯uorescent staining revealed that most of the G418-resistant colonies in the E2F1b transfected culture expressed E2F1b. Random subcloning of ®ve colonies led to the generation of four stable cell lines expressing E2F1b at a protein level higher than endogenous E2F1, suggesting that the expression of E2F1b in these cells was well tolerated. Interestingly, E2F1b stable cell lines exhibited a cell swelling phenotype with the appearance of enlarged and senescence-like cells (Figure 2a) . The morphology has been noted previously when underphosphorylated pRB was expressed in these cells (Huang et al., 1988; Hinds et al., 1992; Qin et al., 1992; Qian et al., 1992) . In addition, we noted that cells stably expressing E2F1b grow slower than the control cells as measured by the growth curve and the time to reach con¯uence ( Figure  2b and data not shown). Therefore, it is likely that E2F1b slowed G 1 progression which led to an accumulative withdrawal from the cell cycle while E2F1a induced a G 1 block.
Introduction of E2F1a led to a speci®c G 1 arrest
Before concluding that E2F1a induces a speci®c G 1 block, it was necessary to rule out the possibility that E2F1a caused a non-speci®c toxic eect which led to irreversible G 1 arrest. Two experiments were done to rule out this possibility. First, two dierent mutations, The cell cycle effects of E2F1 mutants X-Q Qin and J Barsoum both of which speci®cally inactivated the DNA binding property of E2F1 Qin et al., 1995) , were subcloned into E2F1a to create E2F1a132 and E2F1a138. Transient transfection of E2F1a132 and E2F1a138 gave rise to levels of protein expression equivalent to E2F1a. Cell cycle analysis indicated that E2F1a132 and E2F1a138 had signi®cantly reduced eects relative to E2F1a, suggesting that speci®c DNA binding is relevant ( Figure 3 ). Secondly, we tested whether E2F1 could drive the cells past the G 1 block induced by E2F1a. Co-transfection of wild-type E2F1 overrode the E2F1a-induced G 1 block. E2F1b53, a DNA binding defective E2F1 mutant with an intact transactivation domain, failed to override the eect of E2F1a ( Figure 3 ). These experiments indicate that E2F1a did not cause a block in G 1 through non-speci®c toxicity. When E2F1a41, an E2F1a mutant with the Nterminal 40 amino acid residues deleted, was tested, a signi®cant G 1 blockage eect was observed ( Figure 3 ). Therefore, the N-terminus was not critical for the observed eect. These data suggest that E2F1a interfered with the endogenous E2F1 function through speci®c DNA binding, and one biological consequence of this interference is a block in G 1 phase.
E2F1a induced a G 1 arrest after the restriction point, with cells phenotypically at G 2 or M phase
The important control point in G 1 determining whether cell division will occur was characterized as thè restriction point' in mammalian cells (reviewed by Pardee, 1989) . Once passing this point, cells become 20 mg of expression vector or plasmids encoding either E2F1a, E2F1b, or pRB were individually co-transfected with 3 mg of the CD19 expression plasmid pCD19 into SAOS2 cells. Three days after transfection, cells were harvested, stained with anti-CD19 antibody, and examined for DNA content by propidium iodide staining and¯ow cytometry (Qin et al., 1995) . Qin et al., 1994 Qin et al., , 1995 Shan and Lee, 1994; Kowalik et al., 1995; . It is possible that blockage of E2F1 transactivation with a DNA binding competitor, E2F1a, might inhibit cell cycle progression from the start of DNA synthesis. If it is the case, it is likely that cells might have passed the restriction point and committed to the cycle. To explore these possibilities, a plasmid encoding E2F1a or its derivatives carrying subtle mutations, along with a plasmid encoding b-galactosidase was cotransfected into cells. Three days after transfection, cells were stained with X-gal. The morphology of the transfection-positive cells was examined. In the E2F1a-transfected culture, there was a signi®cant increase in the number of cells which manifested round shape with slightly condensed nuclear materials and cells which exhibited mitotic ®gures, suggesting that the cells were phenotypically at G 2 or M phase (Figure 4a and b) . To con®rm that these cells are indeed phenotypically at later stages of the cycle than G 1 we further examined the expression of cyclin B, which accumulates to a maximal level during G 2 and M, by double-immunouorescence staining of the E2F1a transfected cells. As shown in Figure 5 Since expression of E2F1a renders cells phenotypically at a later stage of the cycle but genotypically at the 2N level (G 1 stage), we made two assumptions. First, we reasoned that this phenomenon would be incompatible with the long term cell survival. Secondly, a compromised survival might be accompanied with other cellular alterations. There were two lines of evidence which support the ®rst assumption. First, most cells which received the E2F1a plasmid failed to give rise to stable cell lines as revealed by the colony formation assays (Table 1 ), suggesting that expression of E2F1a is incompatible with continued cell proliferation. Secondly, when monitored by X-gal staining after 1 week of culture, there were dramatically fewer b-gal positive cells left in the culture transfected with E2F1a than in the culture transfected with the vector alone, indicating that the transfection-positive cells did not survive. Next we tested the sensitivity of the stable cell lines expressing E2F1a to X-ray irradiation. As shown in Figure 6 , by 6 days after irradiation with two dierent doses of X-ray treatment, cells stably expressing E2F1a exhibited a much higher sensitivity to killing by X-ray irradiation than the control cells or the cells stably expressing E2F1b. These data suggest that there might be an additive, unrelated toxic eect between E2F1a expression and DNA damage. Alternatively, the ability of cells to stably express E2F1a may require other cellular alterations which contribute to the increased sensitivity of cells to DNA damage. We further examined the cell cycle distribution of E2F1a stable cell lines by FACS analysis. As shown in Figure 7 , there is an increased population of G 2 and M phase cells in the E2F1a stable cell lines relative to control cell lines, which is consistent with the latter possibility that other cellular alterations have occurred in E2F1a stable cell lines. Therefore, it appeared that E2F1a executed a dierent cell cycle eect from E2F1b, although both mutants caused G 1 cell increase as measured by FACS analysis. Thus, while E2F1a induces a G 1 block after the restriction point, E2F1b slows the G 1 progression and induces cell cycle exit prior to the restriction point.
E2F1b promoted the cell cycle withdrawal prior to the restriction point, thereby allowing the initiation of dierentiation in Rb ±/± tumor cells
If expression of E2F1b contributes to cell cycle exit, we would expect that it also promotes dierentiation under suitable conditions. Dierentiation is regulated in two steps, initiation and terminal dierentiation. In skeletal muscle cells, withdrawal from G 1 is the trigger step for initiation of dierentiation (Blau, 1992) . Once initiated, cells will enter the terminal dierentiation pathway upon stimulation by myogenic factors such as myogenin. For SAOS2 cells, lack of functional pRB leads to the inability of cells to withdraw from the cell cycle and failure to enter terminal dierentiation even in the presence of myogenic factors (Gu et al., 1993; Schneider et al., 1994) . To test whether E2F1b can coordinate with myogenic factors to promote terminal dierentiation, E2F1b was transfected into SAOS2 cells stably expressing myogenin. SAOS2-myogenin cells do not express the muscle dierentiation marker, myosin heavy chain (Schneider et al., 1994) . Synthesis of E2F1b, as revealed by immuno¯uorescent staining, led to the appearance of this dierentiation marker ( Figure  8 ). This observation was further con®rmed in an experiment in which the plasmid encoding b-galactosidase was included in the transfections. Visualization of b-galactosidase by its antibody revealed that the positive staining of cells in the E2F1b co-transfected cultures was associated with the expression of the myosin heavy chain (data not shown). These data suggest that E2F1b, by slowing the G 1 phase progression and promoting cell cycle withdrawal from G 1 , triggers the initiation of dierentiation in these cells. Finally, E2F1 has been shown to interact with an increasing number of cellular proteins including cyciln A and DP1 (Pagano et al., 1992; Krek et al., 1994; Bandara et al., 1993; Helin et al., 1993; Krek et al., 1993) . Understanding the mechanisms of the dominant negative eects of E2F1b will require the generation of a series of mutants and subsequent investigation of the correlation between the ability of these mutants to bind individual proteins and the ability to induce the biological eects. These experiments are currently underway. However, preliminary data suggest that the E2F1b eects may not be due simply to its ability to bind to cyclin A, since the lack of cyclin A-binding does not appear to aect the E2F1b-induced G 1 cell accumulation. A C-terminal fragment containing the sequences which are sucient for the interaction with DP1 failed to show the G 1 phase eect, suggesting that binding of DP1 alone does not account for the E2F1b eect. Whether there is an involvement of more than one region in the dominant negative eects induced by E2F1b remains to be further examined.
Discussion
Based on the data presented in this report, we argue that E2F1 has two dierent functions before and after the restriction point in these RB-de®cient tumor cells. Before the restriction point, E2F1 acts as an inhibiting factor for withdrawal from the cycle and entrance into a dierentiation pathway. Expression of its dominant negative mutant, E2F1b, promotes the cell cycle withdrawal of these Rb ±/± tumor cells and results in the initiation of dierentiation pathway. After cells pass the restriction point, the function of E2F1 as a transcription factor with speci®c DNA binding property becomes prominent. At this stage, interruption of its function with the mutant E2F1a, which is capable of binding to DNA, is associated with a situation in which the cells are genotypically arrested at G 1 phase but phenotypically at a later stage of the cycle. This con¯icting situation signi®cantly aects the long term survival of these tumour cells. Together, these data point to the dual regulatory eects of the endogenous E2F1 at two dierent stages of the cyclin cycle in Rb 7/7 tumor cells. However, we can not rule out the possibility that E2F1a might also interfere with the function of other E2F family members such as E2F2, E2F3, E2F4 and E2F5, which are able to bind to same DNA sites as E2F1. Given the facts that E2F1 is a major component of the transcriptionally active`free' E2F species at the G 1 /S transition and in S phase which induces the expression of many growth regulatory genes and that adequate expression of E2F1 alone is sucient for transversing the S phase (Moberg et al., 1996 ; and see reviews by Weinberg, 1995; Nevins, 1992) , interruption of E2F1 function appears to be at least necessary for the expression of the E2F1a-induced cell cycle eects.
The proliferation of mammalian cells is regulated by the cell cycle checkpoints. Normally in G 1 , the checkpoint machinery of non-transformed cells can monitor the continued proliferation and direct cells into a non-replicative state, i.e. either quiescence or dierentiation. During the tumorigenesis process, the normal checkpoint regulation is disrupted, leaving cells incapable of withdrawing from the cell cycle. Human The cell cycle effects of E2F1 mutants X-Q Qin and J Barsoum introduction of pRB into Rb 7/7 tumor cells leads to restoration of the checkpoint function, resulting in G 1 arrest (Huang et al., 1988; Hinds et al., 1992; Qin et al., 1992) . Our study indicates that expression of dominant negative E2F1 mutants could mimic the eect of reintroduction of pRB. This implies that pRB imposes a G 1 phase block at least in part, by negatively regulating E2F1 and that the loss of functional pRB leads to the up-regulation of E2F1 which contributes to abnormal cell growth. Thus, up-regulated E2F1 appears to be a key eector which stimulates cell growth as a result of aberration in the checkpoint machinery of Rb
tumor cells.
Recent studies demonstrated that E2F1 7/7 mice developed multiple phenotypes including testicular atrophy and exocrine gland dysplasia. Strikingly, in older mice, lymphocyte hyperproliferation and tumor development in several tissues were observed (Yamasaki et al., 1996; Field et al., 1996) . These data, together with previous studies, revealed the dual eects of a cellular protein as an oncogene as well as a tumor suppressor. However, much biochemical and functional evidence has indicated that E2F1 is a target of pRB action and pRB-E2F complexes can mediate tumor supppressor function by repressing both E2F-mediated transcription and transcription mediated by other transcription factors (Nevins, 1992; Weintraub et al., 1992 Weintraub et al., , 1995 Helin et al., 1993; Adnane et al., 1995; Bremner et al., 1995; Femington et al., 1993; Qin et al., 1995; Sellers et al., 1995) . Therefore, the tumor development in the E2F1 7/7 mice can be formally explained by inability of pRB to transduce its signal as a tumor suppressor.
Our ®ndings that the dominant interfering E2F1 mutants can either slow the cell cycle progression or speci®cally induce growth arrest support the notion that E2F1 functions as a growth stimulator in human Rb 7/7 tumors. Moreover, our study also de®nes a novel role of E2F1 in the G 1 -to-G 0 transition. Clearly, E2F1 is important for the S phase entry and S phase progression. A set of genes can be activated by E2F1 and their activation coincides with either S phase entry or S phase progression (reviewed by Slansky and Farnham, 1995) . Overexpression of E2F1 is sucient to induce DNA replication in serum-starved cells or in cells blocked in G 1 /G 0 by pRB (Johnson et al., 1994; Qin et al., 1994 Qin et al., , 1995 Shan and Lee, 1994; Kowalik et al., 1995) . Furthermore, E2F1 can cooperate with activated ras to promote oncogenic transformation (Johnson et al., 1994a; Singh et al., 1994; Jooss et al., 1995; Xu et al., 1995) . Here, we document that E2F1 functions as an inhibiting factor for G 0 entry before the restriction point. This may be the case only for the Rb 7/7 tumor cells, since normally E2F1 protein is not synthesized until the G 1 -to-S transition and is absent in serum-starved G 0 cells (Moberg et al., 1996; Kaelin et al., 1992) . Inactivation of pRB function in tumor cells causes the disruption of normal regulation of E2F1 expression, leading to the continued expression of E2F1 in G 1 phase. The upregulated E2F1 will prevent tumor cells from entering G 0 and consequently contribute to continued cell division. In part, this may explain why these tumor cells fail to make the G 1 -to-G 0 transition, unlike nontransformed cell. Therefore, our data indicate that E2F1 executes a crucial regulatory eect at the intersection of G 1 progression and G 0 entry in Rb 7/7 tumor cells. This also might be a mechanism underlying the function of E2F1 potentially as a human oncogene.
We observed that cells stably expressing E2F1b grow slower than cells stably carrying vector or cells stably expressing E2F1a as measured by the growth curve and the time to reach con¯uence. This might be due to the fact that E2F1b promoted an accumulative cell cycle withdrawal. However, we only observed a slight decrease in the G418-resistant colony numbers in the E2F1b transfected culture. The reason for this may be that the cell cycle withdrawal into a terminally nonreplicative state such as senescence is an accumulative process, and it may require multiple rounds of the cell cycle to ®nish. It was documented that re-introduction of pRB leads to dramatic development of senescencelike cells under transient conditions (Huang et al., 1988; Hinds et al, 1992; Qin et al., 1992; Qian et al., 1992; Hiebert, 1993) . In this respect, it appears that pRB may be more potent than E2F1b in promoting withdrawal from the cell cycle in Rb 7/7 tumor cells. Our data suggest that E2F1a inhibited DNA synthesis by competing with endogenous E2F1 for DNA binding in Rb 7/7 tumor cells. This is consistent with the results of Dobrowolski et al., who found that co-injection of an E2F1 fragment encoding only the DNA binding domain (residues 95 to 191) blocked the induction of DNA synthesis mediated by E2F1 in quiescent Balb/c 3T3 cells. Since overexpression of E2F1 can lead to S phase entry from G 0 stage and through G 1 phase, the point in the cell cycle at which the co-injected DNA binding competitor blocks E2F1 transactivation is not clear. Using Rb 7/7 tumor cells, we were able to further characterize a situation in which cells are blocked at a post-commitment G 1 stage. We found that E2F1a only exhibits the G 1 arrest eect after the restriction point. This suggests that E2F1 begins to directly execute its functions as a transcriptional activator only after the cells are about to synthesize DNA. Normally, the cell cycle clock for E2F1 transactivation can be regulated by the cycling of pRB phosphorylation. How E2F1 senses the cell cycle clock and starts to transactivate only at the beginning of S phase in Rb 7/7 tumor cells is a relevant question. It is possible that components of the cellular transcriptional machinery, other than pRB, play a role in regulating the transcriptional activity of E2F1. In this respect, evidence indicates that E2F1 interacts with other cellular transcriptional factors (Karlseder et al., 1996; Lin et al., 1996; Bandara et al., 1993; Krek et al., 1993) .
Finally, our ®ndings may also have an impact on designing gene therapy strategies for certain human Rb 7/7 tumors. With advances in gene delivery systems, it may be possible to treat human cancers through reintroduction of a wild-type tumor suppressor gene. It is known that re-introduction of pRB or p53 into certain human tumor cells inhibits cell growth and inhibits the neoplastic phenotype of the target cells. Nevertheless, gene therapy using tumor suppressor genes may not be ideal. Tumor cells lacking tumor suppressor gene function may have already evolved a mechanism to mutate or destabilize wild-type tumor suppressors and might possess a mechanism to mutate or destabilize the re-introduced tumor suppressors. In particular, it has been shown that several tumor cell lines which have had the Rb gene re-introduced have retained tumorigenicity and have formed progressively growing tumors when injected into mice (Xu et al., 1991; Banerjee et al., 1992) . In addition, delivery of tumor suppressor genes such as p53 might lead to a non-speci®c toxic ect on normal human cells. In contrast, since the up-regulated E2F1 becomes an eector which maintains the continued proliferation in Rb 7/7 tumor cells, introduction of E2F1 mutants should interfere with cell cycle progression only in these tumor cells. Therefore, gene therapy utilizing vectors encoding E2F1 dominant interfering mutants could be used to speci®cally block the growth of Rb 7/7 tumors in vivo.
Materials and methods
Cell culture and DNA transfection
Human osteosarcoma cells SAOS2 were acquired from ATCC. C33A, a human cervical carcinoma cell line, was a gift of Rhonda Brown. The cells were maintained as adherent cultures in Dulbecco's modi®ed Eagle's medium (Sigma for SAOS2 and GIBCO for C33A) supplemented with 10% bovine serum (heat-inactivated Hyclone for SAOS2), 2 mM glutamine, penicillin and streptomycin. All cells were grown at 378C in a humidi®ed, 5% CO 2 -containing atmosphere. For transfections, puri®ed plasmid DNA was introduced into cells by the calcium phosphate precipitation method. After overnight incubation the cells were washed and refed with culture media. Three days after the transfection cells were harvested for cell¯ow-cytometry analysis.
Plasmid construction
The eukaryotic expression plasmids pSG5-E2F1a [pSG5-E2F1 (1-96)], pSG5-E2F1b [pSG5-E2F1(dl8+dl53)] pSG5-E2F1b53 [pSG5-E2F1(dl53)] and pSG5-RB has been described previously (Qin et al., 1995) . To make pSG5-E2F1a132 and pSG5-E2F1a138, the HindIII-SalI EF21 cDNA fragment from either pcDNA-E2F1(132) or pcDNA-E2F1(138) was ®rst used to replace the corresponding wild-type cDNA fragment in pSP72-E2F1(1 ± 196) (Qin et al., 1995) to create pSP72-E2F1a132 and pSP72-E2F1a138. The inserts from the pSP72-E2F1a132 and pSP72-E2F1a138 were further excised as BamHI ± EcoRV fragments and then subcloned into the BamHI ± EcoRV backbone of pSG5-E2F1a. The cDNA inserts of E2F1a and E2F1a138 were further used to a b c Figure 8 Co-expression of E2F1b in SAOS2-myogenin cells permits the expression of the skeletal muscle dierential marker, myosin heavy chain. SAOS2-myogenin cells were derived from permanent transfection of the mouse myogenin expression plasmid pCMV-myogenin in SAOS2 cells (Schneider et al., 1994) . The cells were seeded onto glass coverslips and transfected with the E2F1b expression plasmid and further incubated for 72 h as in references (Gu et al., 1993; Schneider et al., 1994) . After ®xation with paraformaldehyde solution and permeabilization with methanol, double-immuno¯uorescence staining was performed with a rabbit antibody against E2F1 plus an FITC-conjugated goat anti-rabbit antibody (green, a) and a mouse anti-myosin heavy chain antibody NF20 plus a Texas-red conjugated anti-mouse antibody (red, b). The staining-positive cells were scored as cells having the immuno¯uorescence intensity higher than background (see arrows). (c) shows the visualization of nuclei with DAPI staining replace the full-length E2F1 insert in a plasmid encoding HA-E2F1 (Krek et al., 1994) to generate pcHA-E2F1a and pcHA-E2F1a138.
Flow-cytometry analysis
Cells were co-transfected with 3 mg of the CD19-encoding plasmid pCD19 (a gift of Dr Tom Tedder). The cells were trypsinized, washed with PBS containing 0.1% bovine serum albumin and 20 mM HEPES (pH 7.3), and then treated with a monoclonal anti-CD19 antibody (CD19.15; 1 : 500 dilution) for 75 min on ice. The cells were then washed and incubated with an FITC-conjugated goat anti-mouse second antibody (15 mg/ml; Boehringer) for 45 min on ice. The cells were washed again and then ®xed in pre-cooled 70% ethanol at 48C overnight. Prior to analysis, the cells were washed again and then treated with RNase A (5 mg/ml) and propidium iodide solution (69 mM propidium iodide, 38 mM Sodium citrate) for 20 min at 378C. The samples were analysed using a Becton-Dickinson FACScan. Approximately 30 000 cells per sample were analysed.
Immunoblotting
Cells were lysed by rocking for 1 h at 48C in 50 mM TrisHCl (pH 8.0), 200 mM NaCl, 0.5% (v/v) Nonidet P-40 containing 50 mg/ml phenylmethylsulfonyl¯uoride, 10 mg/ ml aprotinin, 10 mg/ml leupeptin, 20 mM NaF, and 0.1 mM sodium orthovanadate. Proteins were resolved on SDS polyacrylamide gels containing 10% acrylamide and 0.3% N,N'-methylene-bisarcylamide. Separated proteins were transferred to Immobilon-P membrane (Millipore) and probed with a rabbit anti-E2F1 antibody followed by alkaline phosphatase conjugated goat anti-rabbit antibody. Protein bands were ®nally visualized using the alkaline phosphatase substrates (BCIP and NBT).
Immuno¯uorescent staining
Cells were grown and transfected on coverslips. Following ®xation with 0.5% paraformaldehyde, cells were permeabilized by immersion in methanol for 2 min at room temperature. Cells were further incubated together with a primary mouse antibody and a primary rabbit antibody. The cells were then visualized with Texas-red conjugated goat anti-mouse antibody (red) and FITC-conjugated goat anti-rabbit antibody (green).
